Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors

Trial Profile

A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubidecarenone (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Berg Pharma
  • Most Recent Events

    • 28 Sep 2019 According to a Berg Pharma media release, Dr. Vivek Subbiah is the primary investigator for this trial.
    • 28 Sep 2019 Results presented in the Berg Pharma media release.
    • 28 Sep 2019 According to a Berg Pharma media release, data from this trial were presented during a poster session at the European Society for Medical Oncology (ESMO) annual meeting in Barcelona.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top